ID   L1CAM_HUMAN             Reviewed;        1257 AA.
AC   P32004; A0AV65; A4ZYW4; B2RMU7; G3XAF4; Q8TA87;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Neural cell adhesion molecule L1;
DE            Short=N-CAM-L1;
DE            Short=NCAM-L1;
DE   AltName: CD_antigen=CD171;
DE   Flags: Precursor;
GN   Name=L1CAM; Synonyms=CAML1, MIC5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=1932117; DOI=10.1016/0167-4781(91)90108-X;
RA   Kobayashi M., Miura M., Asou H., Uyemura K.;
RT   "Molecular cloning of cell adhesion molecule L1 from human nervous
RT   tissue: a comparison of the primary sequences of L1 molecules of
RT   different origin.";
RL   Biochim. Biophys. Acta 1090:238-240(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=1769655;
RA   Hlavin M.L., Lemmon V.;
RT   "Molecular structure and functional testing of human L1CAM: an
RT   interspecies comparison.";
RL   Genomics 11:416-423(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1627459; DOI=10.1007/BF02919404;
RA   Reid R.A., Hemperly J.J.;
RT   "Variants of human L1 cell adhesion molecule arise through alternate
RT   splicing of RNA.";
RL   J. Mol. Neurosci. 3:127-135(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9286695; DOI=10.1006/geno.1997.4822;
RA   Brenner V., Nyakatura G., Rosenthal A., Platzer M.;
RT   "Genomic organization of two novel genes on human Xq28: compact head
RT   to head arrangement of IDH gamma and TRAP delta is conserved in rat
RT   and mouse.";
RL   Genomics 44:8-14(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=9479034; DOI=10.1016/S0378-1119(97)00614-8;
RA   Coutelle O., Nyakatura G., Taudien S., Elgar G., Brenner S.,
RA   Platzer M., Drescher B., Jouet M., Kenwrick S., Rosenthal A.;
RT   "The neural cell adhesion molecule L1: genomic organisation and
RT   differential splicing is conserved between man and the pufferfish
RT   Fugu.";
RL   Gene 208:7-15(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Son Y.S.;
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 20-36.
RX   PubMed=3136168;
RA   Wolff J.M., Frank R., Mujoo K., Spiro R.C., Reisfeld R.A.,
RA   Rathjen F.G.;
RT   "A human brain glycoprotein related to the mouse cell adhesion
RT   molecule L1.";
RL   J. Biol. Chem. 263:11943-11947(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 332-371.
RX   PubMed=2387585; DOI=10.1016/0888-7543(90)90203-7;
RA   Djabali M., Mattei M.-G., Nguyen C., Roux D., Demengeot J.,
RA   Denizot F., Moos M., Schachner M., Goridis C., Jordan B.R.;
RT   "The gene encoding L1, a neural adhesion molecule of the
RT   immunoglobulin family, is located on the X chromosome in mouse and
RT   man.";
RL   Genomics 7:587-593(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 353-1176, AND NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 1082-1176.
RC   TISSUE=Fetal brain;
RX   PubMed=1923824; DOI=10.1093/nar/19.19.5395;
RA   Rosenthal A., Mackinnon R.N., Jones D.S.C.;
RT   "PCR walking from microdissection clone M54 identifies three exons
RT   from the human gene for the neural cell adhesion molecule L1 (CAM-
RT   L1).";
RL   Nucleic Acids Res. 19:5395-5401(1991).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1030-1257.
RX   PubMed=1993895; DOI=10.1111/j.1471-4159.1991.tb01994.x;
RA   Harper J.R., Prince J.T., Healy P.A., Stuart J.K., Nauman S.J.,
RA   Stallcup W.B.;
RT   "Isolation and sequence of partial cDNA clones of human L1: homology
RT   of human and rodent L1 in the cytoplasmic region.";
RL   J. Neurochem. 56:797-804(1991).
RN   [14]
RP   PHOSPHORYLATION AT SER-1181.
RX   PubMed=8592152;
RA   Wong E.V., Schaefer A.W., Landreth G., Lemmon V.;
RT   "Casein kinase II phosphorylates the neural cell adhesion molecule
RT   L1.";
RL   J. Neurochem. 66:779-786(1996).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-671.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1163, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-671.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   INVOLVEMENT IN L1 SYNDROME, VARIANTS 26-TYR--GLU-1257 DEL; ASN-37;
RP   MET-38; 66-GLN--GLU-1257 DEL; 109-GLN--GLU-1257 DEL; 133-GLU--GLU-1257
RP   DEL; 138-TRP--GLU-1257 DEL; ILE-172; GLY-184; 187-MET--VAL-198 DEL;
RP   ASP-254; ARG-276; PRO-313; 366-TRP--GLU-1257 DEL; LYS-369;
RP   423-GLN--GLU-1257 DEL; ARG-480; ASN-516; TYR-516; HIS-525; MET-627;
RP   PRO-645; 662-TRP--GLU-1257 DEL; SER-714; ARG-754; 760-ARG--GLU-1257
RP   DEL; 789-GLN--GLU-1257 DEL; 811-TYR--GLU-1257 DEL; 891-TYR--GLU-1257
RP   DEL; 901-ARG--GLU-1257 DEL; 1064-SER--GLU-1257 DEL; ASN-1071 DEL AND
RP   GLN-1080, VARIANTS HSAS/MASA SER-179; ARG-335 AND MET-752, VARIANT
RP   MASA TYR-202, AND VARIANTS HSAS GLN-184 AND PRO-415.
RX   PubMed=19846429; DOI=10.1136/jmg.2009.071688;
RA   Vos Y.J., de Walle H.E., Bos K.K., Stegeman J.A., Ten Berge A.M.,
RA   Bruining M., van Maarle M.C., Elting M.W., den Hollander N.S.,
RA   Hamel B., Fortuna A.M., Sunde L.E., Stolte-Dijkstra I.,
RA   Schrander-Stumpel C.T., Hofstra R.M.;
RT   "Genotype-phenotype correlations in L1 syndrome: a guide for genetic
RT   counselling and mutation analysis.";
RL   J. Med. Genet. 47:169-175(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1194, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-1177 (ISOFORM 2), PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-1172 (ISOFORM 3), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1177 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1172 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   INVOLVEMENT IN L1 SYNDROME, VARIANTS CYS-635 AND ILE-768, AND
RP   GLYCOSYLATION.
RX   PubMed=22222883; DOI=10.1007/s10048-011-0307-4;
RA   Marx M., Diestel S., Bozon M., Keglowich L., Drouot N., Bouche E.,
RA   Frebourg T., Minz M., Saugier-Veber P., Castellani V., Schaefer M.K.;
RT   "Pathomechanistic characterization of two exonic L1CAM variants
RT   located in trans in an obligate carrier of X-linked hydrocephalus.";
RL   Neurogenetics 13:49-59(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1243, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   VARIANT HSAS TYR-264.
RX   PubMed=8401576; DOI=10.1038/ng0893-331;
RA   Jouet M., Rosenthal A., Macfarlane J., Kenwrick S., Donnai D.;
RT   "A missense mutation confirms the L1 defect in X-linked hydrocephalus
RT   (HSAS).";
RL   Nat. Genet. 4:331-331(1993).
RN   [26]
RP   VARIANT HSAS/MASA LEU-1194.
RX   PubMed=7881431; DOI=10.1093/hmg/3.12.2255;
RA   Fransen E., Schrander-Stumpel C., Vits L., Coucke P., van Camp G.,
RA   Willems P.J.;
RT   "X-linked hydrocephalus and MASA syndrome present in one family are
RT   due to a single missense mutation in exon 28 of the L1CAM gene.";
RL   Hum. Mol. Genet. 3:2255-2256(1994).
RN   [27]
RP   INVOLVEMENT IN MASA, INVOLVEMENT IN HSAS, VARIANTS HSAS GLN-184 AND
RP   ARG-452, AND VARIANT MASA GLN-210.
RX   PubMed=7920659; DOI=10.1038/ng0794-402;
RA   Jouet M., Rosenthal A., Armstrong G., Macfarlane J., Stevenson R.,
RA   Paterson J., Metzenberg A., Ionasescu V., Temple K., Kenwrick S.;
RT   "X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked
RT   hydrocephalus result from mutations in the L1 gene.";
RL   Nat. Genet. 7:402-407(1994).
RN   [28]
RP   VARIANTS MASA GLN-210 AND ASN-598.
RX   PubMed=7920660; DOI=10.1038/ng0794-408;
RA   Vits L., van Camp G., Coucke P., Fransen E., de Boulle K.,
RA   Reyniers E., Korn B., Poustka A., Wilson G., Schrander-Stumpel C.,
RA   Winter R.M., Schwartz C., Willems P.J.;
RT   "MASA syndrome is due to mutations in the neural cell adhesion gene
RT   L1CAM.";
RL   Nat. Genet. 7:408-413(1994).
RN   [29]
RP   VARIANT HSAS/MASA LEU-941, VARIANT MASA LYS-309, AND VARIANTS HSAS
RP   SER-9; SER-121; PHE-768 AND CYS-1070.
RX   PubMed=7762552;
RA   Jouet M., Moncla A., Paterson J., McKeown C., Fryer A., Carpenter N.,
RA   Holmberg E., Wadelius C., Kenwrick S.;
RT   "New domains of neural cell-adhesion molecule L1 implicated in X-
RT   linked hydrocephalus and MASA syndrome.";
RL   Am. J. Hum. Genet. 56:1304-1314(1995).
RN   [30]
RP   VARIANT HSAS/MASA LEU-1194, VARIANTS HSAS GLN-184; TYR-264 AND
RP   ARG-452, AND VARIANTS MASA GLN-210 AND ASN-598.
RX   PubMed=8556302;
RA   Fransen E., Lemmon V., van Camp G., Vits L., Coucke P., Willems P.J.;
RT   "CRASH syndrome: clinical spectrum of corpus callosum hypoplasia,
RT   retardation, adducted thumbs, spastic paraparesis and hydrocephalus
RT   due to mutations in one single gene, L1.";
RL   Eur. J. Hum. Genet. 3:273-284(1995).
RN   [31]
RP   ERRATUM.
RA   Fransen E., Lemmon V., van Camp G., Vits L., Coucke P., Willems P.J.;
RL   Eur. J. Hum. Genet. 4:126-126(1996).
RN   [32]
RP   INVOLVEMENT IN MASA, INVOLVEMENT IN HSAS, AND VARIANTS HSAS/MASA
RP   SER-179 AND ARG-370.
RX   PubMed=7562969; DOI=10.1136/jmg.32.7.549;
RA   Ruiz J.C., Cuppens H., Legius E., Fryns J.-P., Glover T., Marynen P.,
RA   Cassiman J.-J.;
RT   "Mutations in L1-CAM in two families with X linked complicated spastic
RT   paraplegia, MASA syndrome, and HSAS.";
RL   J. Med. Genet. 32:549-552(1995).
RN   [33]
RP   VARIANT HSAS GLU-655.
RX   PubMed=9118141; DOI=10.1007/BF00261591;
RA   Izumoto S., Yamasaki M., Arita N., Hiraga S., Ohnishi T., Fujitani K.,
RA   Sakoda S., Hayakawa T.;
RT   "A new mutation of the L1CAM gene in an X-linked hydrocephalus
RT   family.";
RL   Childs Nerv. Syst. 12:742-747(1996).
RN   [34]
RP   VARIANTS HSAS CYS-194 AND LEU-240.
RX   PubMed=8929944; DOI=10.1136/jmg.33.2.103;
RA   Gu S.-M., Orth U., Veske A., Enders H., Kluender K., Schloesser M.,
RA   Engel W., Schwinger E., Gal A.;
RT   "Five novel mutations in the L1CAM gene in families with X linked
RT   hydrocephalus.";
RL   J. Med. Genet. 33:103-106(1996).
RN   [35]
RP   VARIANT MASA PRO-482, VARIANTS HSAS SER-526 DEL; PRO-542 AND THR-741,
RP   VARIANT HSAS/MASA MET-752, AND VARIANT ILE-768.
RX   PubMed=9268105;
RX   DOI=10.1002/(SICI)1096-8628(19970822)71:3<336::AID-AJMG15>3.0.CO;2-L;
RA   Gu S.-M., Orth U., Zankl M., Schroeder J., Gal A.;
RT   "Molecular analysis of the L1CAM gene in patients with X-linked
RT   hydrocephalus demonstrates eight novel mutations and suggests non-
RT   allelic heterogeneity of the trait.";
RL   Am. J. Med. Genet. 71:336-340(1997).
RN   [36]
RP   VARIANTS MASA ASP-268 AND ASP-426.
RX   PubMed=9300653; DOI=10.1093/hmg/6.10.1625;
RA   Fransen E., Van Camp G., Vits L., Willems P.J.;
RT   "L1-associated diseases: clinical geneticists divide, molecular
RT   geneticists unite.";
RL   Hum. Mol. Genet. 6:1625-1632(1997).
RN   [37]
RP   VARIANTS HSAS GLN-184; 439-VAL--THR-443 DEL; CYS-784 AND
RP   936-LEU--LEU-948 DEL.
RX   PubMed=9195224;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:6<512::AID-HUMU3>3.0.CO;2-3;
RA   Macfarlane J.R., Du J.-S., Pepys M.E., Ramsden S., Donnai D.,
RA   Charlton R., Garrett C., Tolmie J., Yates J.R.W., Berry C., Goudie D.,
RA   Moncla A., Lunt P., Hodgson S., Jouet M., Kenwrick S.;
RT   "Nine novel L1 CAM mutations in families with X-linked
RT   hydrocephalus.";
RL   Hum. Mutat. 9:512-518(1997).
RN   [38]
RP   VARIANT HSAS/MASA ARG-698, VARIANT MASA ASP-691, AND VARIANT HSAS
RP   PRO-935.
RX   PubMed=9521424;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:3<222::AID-HUMU7>3.0.CO;2-J;
RA   Du Y.-Z., Srivastava A.K., Schwartz C.E.;
RT   "Multiple exon screening using restriction endonuclease fingerprinting
RT   (REF): detection of six novel mutations in the L1 cell adhesion
RT   molecule (L1CAM) gene.";
RL   Hum. Mutat. 11:222-230(1998).
RN   [39]
RP   VARIANT MASA PRO-632.
RX   PubMed=9452110;
RA   Vits L., Chitayat D., van Camp G., Holden J.J.A., Fransen E.,
RA   Willems P.J.;
RT   "Evidence for somatic and germline mosaicism in CRASH syndrome.";
RL   Hum. Mutat. Suppl. 1:S284-S287(1998).
RN   [40]
RP   VARIANTS HSAS/MASA ARG-335 AND CYS-473, AND VARIANTS HSAS THR-219;
RP   CYS-386 AND LEU-1224.
RX   PubMed=9744477;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:4<259::AID-HUMU7>3.0.CO;2-A;
RA   Saugier-Veber P., Martin C., le Meur N., Lyonnet S., Munnich A.,
RA   David A., Henocq A., Heron D., Jonveaux P., Odent S., Manouvrier S.,
RA   Moncla A., Morichon N., Philip N., Satge D., Tosi M., Frebourg T.;
RT   "Identification of novel L1CAM mutations using fluorescence-assisted
RT   mismatch analysis.";
RL   Hum. Mutat. 12:259-266(1998).
RN   [41]
RP   VARIANTS MASA CYS-674 AND ASP-691, AND VARIANT HSAS/MASA ARG-698.
RX   PubMed=9832035; DOI=10.1136/jmg.35.11.901;
RA   Michaelis R.C., Du Y.-Z., Schwartz C.E.;
RT   "The site of a missense mutation in the extracellular Ig or FN domains
RT   of L1CAM influences infant mortality and the severity of X linked
RT   hydrocephalus.";
RL   J. Med. Genet. 35:901-904(1998).
RN   [42]
RP   VARIANTS HSAS TRP-184; CYS-335; ILE-408; ASP-421; TYR-497; THR-691 AND
RP   PRO-751, VARIANTS ASN-30; TRP-739 AND GLU-1239, AND VARIANT HSAS/MASA
RP   ARG-370.
RX   PubMed=10797421;
RX   DOI=10.1002/(SICI)1096-8628(20000501)92:1<40::AID-AJMG7>3.0.CO;2-R;
RA   Finckh U., Schroeder J., Ressler B., Veske A., Gal A.;
RT   "Spectrum and detection rate of L1CAM mutations in isolated and
RT   familial cases with clinically suspected L1-disease.";
RL   Am. J. Med. Genet. 92:40-46(2000).
RN   [43]
RP   VARIANT MASA TYR-202.
RX   PubMed=10805190;
RA   Sztriha L., Frossard P., Hofstra R.M., Verlind E., Nork M.;
RT   "Novel missense mutation in the L1 gene in a child with corpus
RT   callosum agenesis, retardation, adducted thumbs, spastic paraparesis,
RT   and hydrocephalus.";
RL   J. Child Neurol. 15:239-243(2000).
RN   [44]
RP   VARIANT HSAS/MASA MET-752, AND POSSIBLE INVOLVEMENT IN HIRSCHSPRUNG
RP   DISEASE.
RX   PubMed=11857550; DOI=10.1002/ajmg.10185;
RA   Parisi M.A., Kapur R.P., Neilson I., Hofstra R.M.W., Holloway L.W.,
RA   Michaelis R.C., Leppig K.A.;
RT   "Hydrocephalus and intestinal aganglionosis: is L1CAM a modifier gene
RT   in Hirschsprung disease?";
RL   Am. J. Med. Genet. 108:51-56(2002).
RN   [45]
RP   VARIANT HSAS PRO-415.
RX   PubMed=12435569; DOI=10.1016/S0887-8994(02)00440-X;
RA   Sztriha L., Vos Y.J., Verlind E., Johansen J., Berg B.;
RT   "X-linked hydrocephalus: a novel missense mutation in the L1CAM
RT   gene.";
RL   Pediatr. Neurol. 27:293-296(2002).
RN   [46]
RP   CHARACTERIZATION OF VARIANT HSAS TYR-264, SUBCELLULAR LOCATION, AND
RP   GLYCOSYLATION.
RX   PubMed=12514225;
RA   Ruenker A.E., Bartsch U., Nave K.A., Schachner M.;
RT   "The C264Y missense mutation in the extracellular domain of L1 impairs
RT   protein trafficking in vitro and in vivo.";
RL   J. Neurosci. 23:277-286(2003).
RN   [47]
RP   VARIANT ACCPX LEU-240.
RX   PubMed=16650080; DOI=10.1111/j.1399-0004.2006.00607.x;
RA   Basel-Vanagaite L., Straussberg R., Friez M.J., Inbar D.,
RA   Korenreich L., Shohat M., Schwartz C.E.;
RT   "Expanding the phenotypic spectrum of L1CAM-associated disease.";
RL   Clin. Genet. 69:414-419(2006).
RN   [48]
RP   VARIANT MASA ASN-770.
RX   PubMed=16816908; DOI=10.1007/s10072-006-0610-2;
RA   Simonati A., Boaretto F., Vettori A., Dabrilli P., Criscuolo L.,
RA   Rizzuto N., Mostacciuolo M.L.;
RT   "A novel missense mutation in the L1CAM gene in a boy with L1
RT   disease.";
RL   Neurol. Sci. 27:114-117(2006).
RN   [49]
RP   CHARACTERIZATION OF VARIANTS HSAS GLN-184 AND LEU-1036, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20621658; DOI=10.1016/j.nbd.2010.05.029;
RA   Schaefer M.K., Nam Y.C., Moumen A., Keglowich L., Bouche E.,
RA   Kueffner M., Bock H.H., Rathjen F.G., Raoul C., Frotscher M.;
RT   "L1 syndrome mutations impair neuronal L1 function at different levels
RT   by divergent mechanisms.";
RL   Neurobiol. Dis. 40:222-237(2010).
RN   [50]
RP   INVOLVEMENT OF VARIANT HSAS/MASA ARG-698 IN HYDROCEPHALUS WITH
RP   HIRSCHSPRUNG DISEASE.
RX   PubMed=22344793; DOI=10.1002/ajmg.a.35244;
RA   Fernandez R.M., Nunez-Torres R., Garcia-Diaz L., de Agustin J.C.,
RA   Antinolo G., Borrego S.;
RT   "Association of X-linked hydrocephalus and Hirschsprung disease:
RT   Report of a new patient with a mutation in the L1CAM gene.";
RL   Am. J. Med. Genet. A 158:816-820(2012).
RN   [51]
RP   CHARACTERIZATION OF VARIANTS MASA GLN-210 AND LYS-309,
RP   CHARACTERIZATION OF VARIANTS HSAS THR-219 AND CYS-264,
RP   CHARACTERIZATION OF VARIANT HSAS/MASA LEU-941, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=22973895; DOI=10.1111/jnc.12015;
RA   Tagliavacca L., Colombo F., Racchetti G., Meldolesi J.;
RT   "L1CAM and its cell-surface mutants: new mechanisms and effects
RT   relevant to the physiology and pathology of neural cells.";
RL   J. Neurochem. 124:397-409(2013).
RN   [52]
RP   CHARACTERIZATION OF VARIANT VAL-120, CHARACTERIZATION OF VARIANTS MASA
RP   GLN-210 AND LYS-309, CHARACTERIZATION OF VARIANTS HSAS GLN-184;
RP   TYR-264 AND CYS-1070, AND MUTAGENESIS OF 1147-LYS--VAL-1153.
RX   PubMed=24155914; DOI=10.1371/journal.pone.0076974;
RA   Kudumala S., Freund J., Hortsch M., Godenschwege T.A.;
RT   "Differential effects of human L1CAM mutations on complementing
RT   guidance and synaptic defects in Drosophila melanogaster.";
RL   PLoS ONE 8:E76974-E76974(2013).
RN   [53]
RP   VARIANT 789-GLN--GLU-1257 DEL, CHARACTERIZATION OF VARIANTS ASN-37;
RP   MET-38 AND ILE-172, CHARACTERIZATION OF VARIANT MASA TYR-202, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=26891472; DOI=10.1111/cge.12763;
RA   Christaller W.A., Vos Y., Gebre-Medhin S., Hofstra R.M.,
RA   Schaefer M.K.;
RT   "L1 syndrome diagnosis complemented with functional analysis of L1CAM
RT   variants located to the two N-terminal Ig-like domains.";
RL   Clin. Genet. 91:115-120(2017).
CC   -!- FUNCTION: Neural cell adhesion molecule involved in the dynamics
CC       of cell adhesion and in the generation of transmembrane signals at
CC       tyrosine kinase receptors. During brain development, critical in
CC       multiple processes, including neuronal migration, axonal growth
CC       and fasciculation, and synaptogenesis. In the mature brain, plays
CC       a role in the dynamics of neuronal structure and function,
CC       including synaptic plasticity. {ECO:0000269|PubMed:20621658,
CC       ECO:0000305}.
CC   -!- SUBUNIT: Interacts with SHTN1; the interaction occurs in axonal
CC       growth cones. {ECO:0000250|UniProtKB:Q05695}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12514225,
CC       ECO:0000269|PubMed:20621658, ECO:0000269|PubMed:22973895,
CC       ECO:0000269|PubMed:26891472}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:Q05695}. Cell projection, growth cone
CC       {ECO:0000250|UniProtKB:Q05695}. Cell projection, axon
CC       {ECO:0000269|PubMed:20621658}. Cell projection, dendrite.
CC       Note=Colocalized with SHTN1 in close apposition with actin
CC       filaments in filopodia and lamellipodia of axonalne growth cones
CC       of hippocampal neurons (By similarity). In neurons, detected
CC       predominantly in axons and cell body, weak localization to
CC       dendrites (PubMed:20621658). {ECO:0000250|UniProtKB:Q05695,
CC       ECO:0000269|PubMed:20621658}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P32004-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P32004-2; Sequence=VSP_002591;
CC         Note=Contains a phosphoserine at position 1177.
CC         {ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692};
CC       Name=3;
CC         IsoId=P32004-3; Sequence=VSP_046317, VSP_002591;
CC         Note=Contains a phosphoserine at position 1172.
CC         {ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692};
CC   -!- DISEASE: Hydrocephalus due to stenosis of the aqueduct of Sylvius
CC       (HSAS) [MIM:307000]: Hydrocephalus is a condition in which
CC       abnormal accumulation of cerebrospinal fluid in the brain causes
CC       increased intracranial pressure inside the skull. This is usually
CC       due to blockage of cerebrospinal fluid outflow in the brain
CC       ventricles or in the subarachnoid space at the base of the brain.
CC       In children is typically characterized by enlargement of the head,
CC       prominence of the forehead, brain atrophy, mental deterioration,
CC       and convulsions. In adults the syndrome includes incontinence,
CC       imbalance, and dementia. HSAS is characterized by mental
CC       retardation and enlarged brain ventricles.
CC       {ECO:0000269|PubMed:10797421, ECO:0000269|PubMed:11857550,
CC       ECO:0000269|PubMed:12435569, ECO:0000269|PubMed:12514225,
CC       ECO:0000269|PubMed:19846429, ECO:0000269|PubMed:20621658,
CC       ECO:0000269|PubMed:22344793, ECO:0000269|PubMed:22973895,
CC       ECO:0000269|PubMed:24155914, ECO:0000269|PubMed:7562969,
CC       ECO:0000269|PubMed:7762552, ECO:0000269|PubMed:7881431,
CC       ECO:0000269|PubMed:7920659, ECO:0000269|PubMed:8401576,
CC       ECO:0000269|PubMed:8556302, ECO:0000269|PubMed:8929944,
CC       ECO:0000269|PubMed:9118141, ECO:0000269|PubMed:9195224,
CC       ECO:0000269|PubMed:9268105, ECO:0000269|PubMed:9521424,
CC       ECO:0000269|PubMed:9744477, ECO:0000269|PubMed:9832035}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry. L1CAM mutations have also been found in few patients
CC       affected by hydrocephalus with Hirschsprung disease, suggesting a
CC       role of this gene acting either in a direct or indirect way in the
CC       pathogenesis of Hirschsprung disease (PubMed:22344793).
CC       {ECO:0000269|PubMed:22344793}.
CC   -!- DISEASE: Mental retardation, aphasia, shuffling gait, and adducted
CC       thumbs syndrome (MASA) [MIM:303350]: An X-linked recessive
CC       syndrome with a highly variable clinical spectrum. Main clinical
CC       features include spasticity and hyperreflexia of lower limbs,
CC       shuffling gait, mental retardation, aphasia and adducted thumbs.
CC       The features of spasticity have been referred to as complicated
CC       spastic paraplegia type 1 (SPG1). Some patients manifest corpus
CC       callosum hypoplasia and hydrocephalus. Inter- and intrafamilial
CC       variability is very wide, such that patients with hydrocephalus,
CC       MASA, SPG1, and agenesis of corpus callosum can be present within
CC       the same family. {ECO:0000269|PubMed:10797421,
CC       ECO:0000269|PubMed:10805190, ECO:0000269|PubMed:11857550,
CC       ECO:0000269|PubMed:16816908, ECO:0000269|PubMed:19846429,
CC       ECO:0000269|PubMed:22344793, ECO:0000269|PubMed:22973895,
CC       ECO:0000269|PubMed:24155914, ECO:0000269|PubMed:26891472,
CC       ECO:0000269|PubMed:7562969, ECO:0000269|PubMed:7762552,
CC       ECO:0000269|PubMed:7881431, ECO:0000269|PubMed:7920659,
CC       ECO:0000269|PubMed:7920660, ECO:0000269|PubMed:8556302,
CC       ECO:0000269|PubMed:9268105, ECO:0000269|PubMed:9300653,
CC       ECO:0000269|PubMed:9452110, ECO:0000269|PubMed:9521424,
CC       ECO:0000269|PubMed:9744477, ECO:0000269|PubMed:9832035}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Defects in L1CAM may contribute to Hirschsprung
CC       disease by modifying the effects of Hirschsprung disease-
CC       associated genes to cause intestinal aganglionosis.
CC       {ECO:0000269|PubMed:11857550}.
CC   -!- DISEASE: Agenesis of the corpus callosum, X-linked, partial
CC       (ACCPX) [MIM:304100]: A syndrome characterized by partial corpus
CC       callosum agenesis, hypoplasia of inferior vermis and cerebellum,
CC       mental retardation, seizures and spasticity. Other features
CC       include microcephaly, unusual facies, and Hirschsprung disease in
CC       some patients. {ECO:0000269|PubMed:16650080}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in L1CAM are associated with a wide
CC       phenotypic spectrum which varies from severe hydrocephalus and
CC       prenatal death (HSAS) to a milder phenotype (MASA). These
CC       variations may even occur within the same family. Due to the
CC       overlap of phenotypes between HSAS and MASA, many authors use the
CC       general concept of L1 syndrome which covers both ends of the
CC       spectrum. {ECO:0000269|PubMed:19846429,
CC       ECO:0000269|PubMed:22222883, ECO:0000269|PubMed:26891472}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC       L1/neurofascin/NgCAM family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/L1CAMID44110chXq28.html";
CC   -!- WEB RESOURCE: Name=L1CAM; Note=L1CAM mutation Web Page;
CC       URL="http://www.l1cammutationdatabase.info/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X59847; CAA42508.1; -; mRNA.
DR   EMBL; M77640; AAC14352.1; -; mRNA.
DR   EMBL; M74387; AAA59476.1; -; mRNA.
DR   EMBL; U52111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z29373; CAA82564.1; -; Genomic_DNA.
DR   EMBL; EF506611; ABP88252.1; -; mRNA.
DR   EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471172; EAW72787.1; -; Genomic_DNA.
DR   EMBL; BC025843; AAH25843.1; -; mRNA.
DR   EMBL; BC126229; AAI26230.1; -; mRNA.
DR   EMBL; BC136447; AAI36448.1; -; mRNA.
DR   EMBL; M55271; AAA36353.1; ALT_SEQ; mRNA.
DR   EMBL; X58775; CAA41576.1; -; Genomic_DNA.
DR   EMBL; X58776; CAB37831.1; -; mRNA.
DR   CCDS; CCDS14733.1; -. [P32004-1]
DR   CCDS; CCDS14734.1; -. [P32004-2]
DR   CCDS; CCDS48192.1; -. [P32004-3]
DR   PIR; A41060; A41060.
DR   RefSeq; NP_000416.1; NM_000425.4. [P32004-1]
DR   RefSeq; NP_001137435.1; NM_001143963.2. [P32004-3]
DR   RefSeq; NP_001265045.1; NM_001278116.1. [P32004-1]
DR   RefSeq; NP_076493.1; NM_024003.3. [P32004-2]
DR   UniGene; Hs.522818; -.
DR   DisProt; DP00666; -.
DR   ProteinModelPortal; P32004; -.
DR   SMR; P32004; -.
DR   BioGrid; 110094; 23.
DR   IntAct; P32004; 4.
DR   MINT; MINT-1369985; -.
DR   STRING; 9606.ENSP00000359074; -.
DR   iPTMnet; P32004; -.
DR   PhosphoSitePlus; P32004; -.
DR   SwissPalm; P32004; -.
DR   DMDM; 1705571; -.
DR   EPD; P32004; -.
DR   MaxQB; P32004; -.
DR   PaxDb; P32004; -.
DR   PeptideAtlas; P32004; -.
DR   PRIDE; P32004; -.
DR   Ensembl; ENST00000361699; ENSP00000355380; ENSG00000198910. [P32004-2]
DR   Ensembl; ENST00000361981; ENSP00000354712; ENSG00000198910. [P32004-3]
DR   Ensembl; ENST00000370055; ENSP00000359072; ENSG00000198910. [P32004-3]
DR   Ensembl; ENST00000370060; ENSP00000359077; ENSG00000198910. [P32004-1]
DR   GeneID; 3897; -.
DR   KEGG; hsa:3897; -.
DR   UCSC; uc004fjc.5; human. [P32004-1]
DR   CTD; 3897; -.
DR   DisGeNET; 3897; -.
DR   GeneCards; L1CAM; -.
DR   GeneReviews; L1CAM; -.
DR   HGNC; HGNC:6470; L1CAM.
DR   HPA; CAB010896; -.
DR   HPA; HPA005830; -.
DR   MalaCards; L1CAM; -.
DR   MIM; 303350; phenotype.
DR   MIM; 304100; phenotype.
DR   MIM; 307000; phenotype.
DR   MIM; 308840; gene.
DR   neXtProt; NX_P32004; -.
DR   OpenTargets; ENSG00000198910; -.
DR   Orphanet; 2182; Hydrocephalus with stenosis of the aqueduct of Sylvius.
DR   Orphanet; 2466; MASA syndrome.
DR   Orphanet; 1497; X-linked complicated corpus callosum dysgenesis.
DR   Orphanet; 306617; X-linked complicated spastic paraplegia type 1.
DR   PharmGKB; PA30259; -.
DR   eggNOG; KOG3513; Eukaryota.
DR   eggNOG; ENOG410XSVG; LUCA.
DR   GeneTree; ENSGT00760000118840; -.
DR   HOGENOM; HOG000231380; -.
DR   HOVERGEN; HBG000144; -.
DR   InParanoid; P32004; -.
DR   KO; K06550; -.
DR   OMA; MDWNAPQ; -.
DR   OrthoDB; EOG091G00LY; -.
DR   PhylomeDB; P32004; -.
DR   TreeFam; TF351098; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-373760; L1CAM interactions.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   SIGNOR; P32004; -.
DR   ChiTaRS; L1CAM; human.
DR   GeneWiki; L1_(protein); -.
DR   GenomeRNAi; 3897; -.
DR   PMAP-CutDB; P32004; -.
DR   PRO; PR:P32004; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000198910; -.
DR   CleanEx; HS_L1CAM; -.
DR   ExpressionAtlas; P32004; baseline and differential.
DR   Genevisible; P32004; HS.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0044295; C:axonal growth cone; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043025; C:neuronal cell body; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:CAFA.
DR   GO; GO:0061564; P:axon development; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; NAS:ProtInc.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0031175; P:neuron projection development; IDA:UniProtKB.
DR   GO; GO:0045773; P:positive regulation of axon extension; ISS:UniProtKB.
DR   GO; GO:0050808; P:synapse organization; IDA:UniProtKB.
DR   CDD; cd00063; FN3; 4.
DR   Gene3D; 2.60.40.10; -; 11.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR026966; Neurofascin/L1/NrCAM_C.
DR   Pfam; PF13882; Bravo_FIGEY; 1.
DR   Pfam; PF00041; fn3; 4.
DR   Pfam; PF07679; I-set; 2.
DR   SMART; SM00060; FN3; 4.
DR   SMART; SM00409; IG; 6.
DR   SMART; SM00408; IGc2; 5.
DR   SUPFAM; SSF48726; SSF48726; 6.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   PROSITE; PS50853; FN3; 5.
DR   PROSITE; PS50835; IG_LIKE; 6.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell adhesion; Cell membrane; Cell projection;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hereditary spastic paraplegia; Hirschsprung disease;
KW   Immunoglobulin domain; Membrane; Mental retardation;
KW   Neurodegeneration; Neurogenesis; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:3136168}.
FT   CHAIN        20   1257       Neural cell adhesion molecule L1.
FT                                /FTId=PRO_0000015022.
FT   TOPO_DOM     20   1120       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1121   1143       Helical. {ECO:0000255}.
FT   TOPO_DOM   1144   1257       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       35    125       Ig-like C2-type 1.
FT   DOMAIN      139    226       Ig-like C2-type 2.
FT   DOMAIN      240    328       Ig-like C2-type 3.
FT   DOMAIN      333    420       Ig-like C2-type 4.
FT   DOMAIN      425    507       Ig-like C2-type 5.
FT   DOMAIN      518    607       Ig-like C2-type 6.
FT   DOMAIN      615    712       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      717    810       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      814    916       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      920   1015       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1016   1115       Fibronectin type-III 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   MOTIF       554    556       Cell attachment site. {ECO:0000255}.
FT   MOD_RES    1163   1163       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983}.
FT   MOD_RES    1178   1178       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P11627}.
FT   MOD_RES    1181   1181       Phosphoserine; by CaMK2.
FT                                {ECO:0000269|PubMed:8592152}.
FT   MOD_RES    1194   1194       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1243   1243       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1244   1244       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P11627}.
FT   MOD_RES    1248   1248       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    203    203       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    247    247       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    294    294       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    433    433       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    479    479       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    490    490       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    505    505       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    588    588       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    671    671       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    726    726       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    777    777       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    825    825       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    849    849       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    876    876       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    979    979       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1022   1022       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1030   1030       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1071   1071       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1105   1105       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     57    114       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    158    209       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    264    312       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    354    404       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    448    497       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    539    591       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ      26     31       YEGHHV -> L (in isoform 3).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_046317.
FT   VAR_SEQ    1177   1180       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:1627459,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_002591.
FT   VARIANT       9      9       W -> S (in HSAS).
FT                                {ECO:0000269|PubMed:7762552}.
FT                                /FTId=VAR_003921.
FT   VARIANT      26   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078350.
FT   VARIANT      30     30       H -> N. {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030403.
FT   VARIANT      37     37       I -> N (probable disease-associated
FT                                mutation found in L1 syndrome; loss of
FT                                localization at the cell surface;
FT                                retention in the endoplasmic reticulum;
FT                                loss of homophilic interactions at the
FT                                cell surface).
FT                                {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:26891472}.
FT                                /FTId=VAR_078351.
FT   VARIANT      38     38       T -> M (no effect on localization at the
FT                                cell surface).
FT                                {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:26891472}.
FT                                /FTId=VAR_078352.
FT   VARIANT      66   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078353.
FT   VARIANT     109   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078354.
FT   VARIANT     120    120       L -> V (no effect on axon guidance
FT                                activity, nor on synapse formation, when
FT                                assayed in a heterologous system;
FT                                dbSNP:rs796052697).
FT                                {ECO:0000269|PubMed:24155914}.
FT                                /FTId=VAR_078355.
FT   VARIANT     121    121       G -> S (in HSAS).
FT                                {ECO:0000269|PubMed:7762552}.
FT                                /FTId=VAR_003922.
FT   VARIANT     133   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078356.
FT   VARIANT     138   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078357.
FT   VARIANT     172    172       M -> I (found in a patient with L1
FT                                syndrome; unknown pathological
FT                                significance; loss of homophilic
FT                                interactions at the cell surface; no
FT                                effect on the localization at the cell
FT                                surface). {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:26891472}.
FT                                /FTId=VAR_078358.
FT   VARIANT     179    179       I -> S (in HSAS and MASA;
FT                                dbSNP:rs137852523).
FT                                {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:7562969}.
FT                                /FTId=VAR_003923.
FT   VARIANT     184    184       R -> G (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078359.
FT   VARIANT     184    184       R -> Q (in HSAS; severe; reduced axon
FT                                arborization; partial loss of
FT                                localization at the cell surface;
FT                                retention in the endoplasmic reticulum;
FT                                in neurons, restricted to cell bodies and
FT                                proximal segments of processes; loss of
FT                                axon guidance and of proper synapse
FT                                formation, when assayed in a heterologous
FT                                system; dbSNP:rs137852521).
FT                                {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:20621658,
FT                                ECO:0000269|PubMed:24155914,
FT                                ECO:0000269|PubMed:7920659,
FT                                ECO:0000269|PubMed:8556302,
FT                                ECO:0000269|PubMed:9195224}.
FT                                /FTId=VAR_003924.
FT   VARIANT     184    184       R -> W (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030404.
FT   VARIANT     187    198       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078360.
FT   VARIANT     194    194       Y -> C (in HSAS).
FT                                {ECO:0000269|PubMed:8929944}.
FT                                /FTId=VAR_003925.
FT   VARIANT     202    202       D -> Y (in MASA; loss of homophilic
FT                                interactions at the cell surface; no
FT                                effect on localization at the cell
FT                                surface). {ECO:0000269|PubMed:10805190,
FT                                ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:26891472}.
FT                                /FTId=VAR_030405.
FT   VARIANT     210    210       H -> Q (in MASA; decrease in cell-matrix
FT                                adhesion; decreased cell migration; loss
FT                                of axon guidance and of proper synapse
FT                                formation, when assayed in a heterologous
FT                                system; no effect on the localization at
FT                                the cell surface; no effect on cell
FT                                proliferation, when transfected in
FT                                pheochromocytoma PC12 cells; no effect on
FT                                neurite outgrowth, when assayed in NGF-
FT                                treated pheochromocytoma PC12 cells;
FT                                dbSNP:rs28933683).
FT                                {ECO:0000269|PubMed:22973895,
FT                                ECO:0000269|PubMed:24155914,
FT                                ECO:0000269|PubMed:7920659,
FT                                ECO:0000269|PubMed:7920660,
FT                                ECO:0000269|PubMed:8556302}.
FT                                /FTId=VAR_003926.
FT   VARIANT     219    219       I -> T (in HSAS; decrease in cell-matrix
FT                                adhesion; decreased cell migration; no
FT                                effect on the localization at the cell
FT                                surface; no effect on cell proliferation,
FT                                when transfected in pheochromocytoma PC12
FT                                cells; no effect on neurite outgrowth,
FT                                when assayed in NGF-treated
FT                                pheochromocytoma PC12 cells).
FT                                {ECO:0000269|PubMed:22973895,
FT                                ECO:0000269|PubMed:9744477}.
FT                                /FTId=VAR_003927.
FT   VARIANT     240    240       P -> L (in HSAS and ACCPX;
FT                                dbSNP:rs137852526).
FT                                {ECO:0000269|PubMed:16650080,
FT                                ECO:0000269|PubMed:8929944}.
FT                                /FTId=VAR_003928.
FT   VARIANT     254    254       A -> D (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078361.
FT   VARIANT     264    264       C -> Y (in HSAS; severe; loss of
FT                                localization to the cell surface;
FT                                retention in the endoplasmic reticulum;
FT                                loss of axon guidance, when assayed in a
FT                                heterologous system; dbSNP:rs137852518).
FT                                {ECO:0000269|PubMed:12514225,
FT                                ECO:0000269|PubMed:22973895,
FT                                ECO:0000269|PubMed:24155914,
FT                                ECO:0000269|PubMed:8401576,
FT                                ECO:0000269|PubMed:8556302}.
FT                                /FTId=VAR_003929.
FT   VARIANT     268    268       G -> D (in MASA).
FT                                {ECO:0000269|PubMed:9300653}.
FT                                /FTId=VAR_030406.
FT   VARIANT     276    276       W -> R (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078362.
FT   VARIANT     309    309       E -> K (in MASA; decrease in neurite
FT                                outgrowth, when assayed in NGF-treated
FT                                pheochromocytoma PC12 cells; decrease in
FT                                cell-matrix adhesion; decreased cell
FT                                migration; no effect on axon guidance, on
FT                                subcellular location to synaptic
FT                                terminals, nor on proper synapse
FT                                formation, when assayed in a heterologous
FT                                system; no effect on the localization at
FT                                the cell surface; no effect on cell
FT                                proliferation, when transfected in
FT                                pheochromocytoma PC12 cells;
FT                                dbSNP:rs367665974).
FT                                {ECO:0000269|PubMed:22973895,
FT                                ECO:0000269|PubMed:24155914,
FT                                ECO:0000269|PubMed:7762552}.
FT                                /FTId=VAR_003930.
FT   VARIANT     313    313       L -> P (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078363.
FT   VARIANT     335    335       W -> C (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030407.
FT   VARIANT     335    335       W -> R (in HSAS and MASA; also in a
FT                                patient with hydrocephalus and
FT                                Hirschsprung disease).
FT                                {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:9744477}.
FT                                /FTId=VAR_003931.
FT   VARIANT     366   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078364.
FT   VARIANT     369    369       N -> K (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078365.
FT   VARIANT     370    370       G -> R (in HSAS and MASA;
FT                                dbSNP:rs137852524).
FT                                {ECO:0000269|PubMed:10797421,
FT                                ECO:0000269|PubMed:7562969}.
FT                                /FTId=VAR_003932.
FT   VARIANT     386    386       R -> C (in HSAS).
FT                                {ECO:0000269|PubMed:9744477}.
FT                                /FTId=VAR_003933.
FT   VARIANT     408    408       N -> I (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030408.
FT   VARIANT     415    415       A -> P (in HSAS).
FT                                {ECO:0000269|PubMed:12435569,
FT                                ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_027512.
FT   VARIANT     421    421       V -> D (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030409.
FT   VARIANT     423   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078366.
FT   VARIANT     426    426       A -> D (in MASA).
FT                                {ECO:0000269|PubMed:9300653}.
FT                                /FTId=VAR_030410.
FT   VARIANT     439    443       Missing (in HSAS).
FT                                {ECO:0000269|PubMed:9195224}.
FT                                /FTId=VAR_003934.
FT   VARIANT     452    452       G -> R (in HSAS; severe;
FT                                dbSNP:rs137852520).
FT                                {ECO:0000269|PubMed:7920659,
FT                                ECO:0000269|PubMed:8556302}.
FT                                /FTId=VAR_003935.
FT   VARIANT     473    473       R -> C (in HSAS and MASA).
FT                                {ECO:0000269|PubMed:9744477}.
FT                                /FTId=VAR_003936.
FT   VARIANT     480    480       G -> R (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078367.
FT   VARIANT     482    482       L -> P (in MASA).
FT                                {ECO:0000269|PubMed:9268105}.
FT                                /FTId=VAR_030411.
FT   VARIANT     497    497       C -> Y (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030412.
FT   VARIANT     516    516       D -> N (found in a patient with L1
FT                                syndrome; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078368.
FT   VARIANT     516    516       D -> Y (found in a patient with L1
FT                                syndrome; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078369.
FT   VARIANT     525    525       R -> H (found in a patient with L1
FT                                syndrome; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078370.
FT   VARIANT     526    526       Missing (in HSAS).
FT                                {ECO:0000269|PubMed:9268105}.
FT                                /FTId=VAR_030413.
FT   VARIANT     542    542       S -> P (in HSAS).
FT                                {ECO:0000269|PubMed:9268105}.
FT                                /FTId=VAR_030414.
FT   VARIANT     598    598       D -> N (in MASA; dbSNP:rs137852519).
FT                                {ECO:0000269|PubMed:7920660,
FT                                ECO:0000269|PubMed:8556302}.
FT                                /FTId=VAR_003937.
FT   VARIANT     627    627       T -> M. {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078371.
FT   VARIANT     632    632       R -> P (in MASA).
FT                                {ECO:0000269|PubMed:9452110}.
FT                                /FTId=VAR_003938.
FT   VARIANT     635    635       W -> C (probable disease-associated
FT                                mutation found in L1 syndrome; loss of
FT                                localization at the cell surface;
FT                                retention in the endoplasmic reticulum;
FT                                loss of transport into axons; loss of
FT                                neurite outgrowth; loss of cell-cell
FT                                adhesion). {ECO:0000269|PubMed:22222883}.
FT                                /FTId=VAR_078372.
FT   VARIANT     645    645       I -> P (probable disease-associated
FT                                mutation found in L1 syndrome; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078373.
FT   VARIANT     655    655       K -> E (in HSAS).
FT                                {ECO:0000269|PubMed:9118141}.
FT                                /FTId=VAR_030415.
FT   VARIANT     662   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078374.
FT   VARIANT     674    674       S -> C (in MASA; associated with callosal
FT                                agenesis). {ECO:0000269|PubMed:9832035}.
FT                                /FTId=VAR_027513.
FT   VARIANT     691    691       A -> D (in MASA; associated with callosal
FT                                agenesis). {ECO:0000269|PubMed:9521424,
FT                                ECO:0000269|PubMed:9832035}.
FT                                /FTId=VAR_003939.
FT   VARIANT     691    691       A -> T (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030416.
FT   VARIANT     698    698       G -> R (in HSAS and MASA; associated with
FT                                callosal agenesis; also found in a
FT                                patient affected by hydrocephalus with
FT                                Hirschsprung disease).
FT                                {ECO:0000269|PubMed:9521424,
FT                                ECO:0000269|PubMed:9832035}.
FT                                /FTId=VAR_003940.
FT   VARIANT     714    714       P -> S (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078375.
FT   VARIANT     739    739       R -> W (in dbSNP:rs142424573).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030417.
FT   VARIANT     741    741       M -> T (in HSAS).
FT                                {ECO:0000269|PubMed:9268105}.
FT                                /FTId=VAR_030418.
FT   VARIANT     751    751       R -> P (in HSAS).
FT                                {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030419.
FT   VARIANT     752    752       V -> M (in HSAS and MASA; also found in a
FT                                patient with the diagnosis of L1
FT                                syndrome; also in a patient with
FT                                hydrocephalus and Hirschsprung disease;
FT                                dbSNP:rs137852525).
FT                                {ECO:0000269|PubMed:11857550,
FT                                ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:9268105}.
FT                                /FTId=VAR_014421.
FT   VARIANT     754    754       W -> R (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078376.
FT   VARIANT     760   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078377.
FT   VARIANT     768    768       V -> F (in HSAS).
FT                                {ECO:0000269|PubMed:7762552}.
FT                                /FTId=VAR_003941.
FT   VARIANT     768    768       V -> I (decreased cell-cell adhesion; no
FT                                effect on subcellular localization; no
FT                                effect on neurite outgrowth;
FT                                dbSNP:rs36021462).
FT                                {ECO:0000269|PubMed:22222883,
FT                                ECO:0000269|PubMed:9268105}.
FT                                /FTId=VAR_030420.
FT   VARIANT     770    770       D -> N (in MASA; associated with callosal
FT                                agenesis; dbSNP:rs148516831).
FT                                {ECO:0000269|PubMed:16816908}.
FT                                /FTId=VAR_027514.
FT   VARIANT     784    784       Y -> C (in HSAS; dbSNP:rs797045674).
FT                                {ECO:0000269|PubMed:9195224}.
FT                                /FTId=VAR_003942.
FT   VARIANT     789   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429,
FT                                ECO:0000269|PubMed:26891472}.
FT                                /FTId=VAR_078378.
FT   VARIANT     811   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078379.
FT   VARIANT     891   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078380.
FT   VARIANT     901   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078381.
FT   VARIANT     935    935       L -> P (in HSAS).
FT                                {ECO:0000269|PubMed:9521424}.
FT                                /FTId=VAR_003943.
FT   VARIANT     936    948       Missing (in HSAS).
FT                                {ECO:0000269|PubMed:9195224}.
FT                                /FTId=VAR_003944.
FT   VARIANT     941    941       P -> L (in HSAS and MASA; decrease in
FT                                neurite outgrowth, when assayed in NGF-
FT                                treated pheochromocytoma PC12 cells;
FT                                decrease in cell-matrix adhesion;
FT                                decreased cell migration; no effect on
FT                                the localization at the cell surface; no
FT                                effect on cell proliferation, when
FT                                transfected in pheochromocytoma PC12
FT                                cells). {ECO:0000269|PubMed:22973895,
FT                                ECO:0000269|PubMed:7762552}.
FT                                /FTId=VAR_003945.
FT   VARIANT     958    958       L -> V (in dbSNP:rs35902890).
FT                                /FTId=VAR_059413.
FT   VARIANT    1036   1036       W -> L (in HSAS; partial loss of
FT                                localization at the cell surface;
FT                                retention in the endoplasmic reticulum;
FT                                in neurons, partial loss of localization
FT                                to axons, but enriched on proximal
FT                                dendrites).
FT                                {ECO:0000269|PubMed:20621658}.
FT                                /FTId=VAR_078382.
FT   VARIANT    1064   1257       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078383.
FT   VARIANT    1070   1070       Y -> C (in HSAS; partial loss of axon
FT                                guidance and loss of proper synapse
FT                                formation, when assayed in a heterologous
FT                                system). {ECO:0000269|PubMed:24155914,
FT                                ECO:0000269|PubMed:7762552}.
FT                                /FTId=VAR_003946.
FT   VARIANT    1071   1071       Missing (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078384.
FT   VARIANT    1080   1080       L -> Q (probable disease-associated
FT                                mutation found in L1 syndrome).
FT                                {ECO:0000269|PubMed:19846429}.
FT                                /FTId=VAR_078385.
FT   VARIANT    1194   1194       S -> L (in HSAS and MASA;
FT                                dbSNP:rs137852522).
FT                                {ECO:0000269|PubMed:7881431,
FT                                ECO:0000269|PubMed:8556302}.
FT                                /FTId=VAR_003947.
FT   VARIANT    1224   1224       S -> L (in HSAS).
FT                                {ECO:0000269|PubMed:9744477}.
FT                                /FTId=VAR_003948.
FT   VARIANT    1239   1239       G -> E. {ECO:0000269|PubMed:10797421}.
FT                                /FTId=VAR_030421.
FT   MUTAGEN    1147   1153       KGGKYSV->AGGAASA: Loss of axon guidance,
FT                                when assayed in a heterologous system,
FT                                but normal synapse formation.
FT                                {ECO:0000269|PubMed:24155914}.
FT   CONFLICT      4      4       A -> V (in Ref. 1; CAA42508).
FT                                {ECO:0000305}.
FT   CONFLICT    216    216       T -> I (in Ref. 1; CAA42508).
FT                                {ECO:0000305}.
FT   CONFLICT    250    250       S -> T (in Ref. 1; CAA42508).
FT                                {ECO:0000305}.
FT   CONFLICT    276    277       WL -> SV (in Ref. 1; CAA42508).
FT                                {ECO:0000305}.
FT   CONFLICT    288    288       V -> A (in Ref. 6; ABP88252).
FT                                {ECO:0000305}.
FT   CONFLICT    357    357       Q -> E (in Ref. 1; CAA42508).
FT                                {ECO:0000305}.
FT   CONFLICT    515    515       K -> T (in Ref. 6; ABP88252).
FT                                {ECO:0000305}.
FT   CONFLICT    626    626       L -> V (in Ref. 1; CAA42508).
FT                                {ECO:0000305}.
FT   CONFLICT    660    660       E -> G (in Ref. 6; ABP88252).
FT                                {ECO:0000305}.
FT   CONFLICT    936    936       L -> V (in Ref. 12; CAB37831).
FT                                {ECO:0000305}.
FT   CONFLICT   1116   1117       GF -> WLC (in Ref. 13; no nucleotide
FT                                entry). {ECO:0000305}.
FT   CONFLICT   1164   1164       E -> V (in Ref. 6; ABP88252).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1257 AA;  140003 MW;  5EDD764DA86C0E63 CRC64;
     MVVALRYVWP LLLCSPCLLI QIPEEYEGHH VMEPPVITEQ SPRRLVVFPT DDISLKCEAS
     GKPEVQFRWT RDGVHFKPKE ELGVTVYQSP HSGSFTITGN NSNFAQRFQG IYRCFASNKL
     GTAMSHEIRL MAEGAPKWPK ETVKPVEVEE GESVVLPCNP PPSAEPLRIY WMNSKILHIK
     QDERVTMGQN GNLYFANVLT SDNHSDYICH AHFPGTRTII QKEPIDLRVK ATNSMIDRKP
     RLLFPTNSSS HLVALQGQPL VLECIAEGFP TPTIKWLRPS GPMPADRVTY QNHNKTLQLL
     KVGEEDDGEY RCLAENSLGS ARHAYYVTVE AAPYWLHKPQ SHLYGPGETA RLDCQVQGRP
     QPEVTWRING IPVEELAKDQ KYRIQRGALI LSNVQPSDTM VTQCEARNRH GLLLANAYIY
     VVQLPAKILT ADNQTYMAVQ GSTAYLLCKA FGAPVPSVQW LDEDGTTVLQ DERFFPYANG
     TLGIRDLQAN DTGRYFCLAA NDQNNVTIMA NLKVKDATQI TQGPRSTIEK KGSRVTFTCQ
     ASFDPSLQPS ITWRGDGRDL QELGDSDKYF IEDGRLVIHS LDYSDQGNYS CVASTELDVV
     ESRAQLLVVG SPGPVPRLVL SDLHLLTQSQ VRVSWSPAED HNAPIEKYDI EFEDKEMAPE
     KWYSLGKVPG NQTSTTLKLS PYVHYTFRVT AINKYGPGEP SPVSETVVTP EAAPEKNPVD
     VKGEGNETTN MVITWKPLRW MDWNAPQVQY RVQWRPQGTR GPWQEQIVSD PFLVVSNTST
     FVPYEIKVQA VNSQGKGPEP QVTIGYSGED YPQAIPELEG IEILNSSAVL VKWRPVDLAQ
     VKGHLRGYNV TYWREGSQRK HSKRHIHKDH VVVPANTTSV ILSGLRPYSS YHLEVQAFNG
     RGSGPASEFT FSTPEGVPGH PEALHLECQS NTSLLLRWQP PLSHNGVLTG YVLSYHPLDE
     GGKGQLSFNL RDPELRTHNL TDLSPHLRYR FQLQATTKEG PGEAIVREGG TMALSGISDF
     GNISATAGEN YSVVSWVPKE GQCNFRFHIL FKALGEEKGG ASLSPQYVSY NQSSYTQWDL
     QPDTDYEIHL FKERMFRHQM AVKTNGTGRV RLPPAGFATE GWFIGFVSAI ILLLLVLLIL
     CFIKRSKGGK YSVKDKEDTQ VDSEARPMKD ETFGEYRSLE SDNEEKAFGS SQPSLNGDIK
     PLGSDDSLAD YGGSVDVQFN EDGSFIGQYS GKKEKEAAGG NDSSGATSPI NPAVALE
//
